TP53 and hematologic disorder: It was been reported that miR-33 could inhibit cell apoptosis and control hematopoietic stem cells (HSC) self-renewal by targeting p53 [47,48], and that this function of miR-33 could be applied to the prevention and treatment of hematopoietic disease.